<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-108338</identifier>
<setSpec>2253-654x</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Metabolic and osteogenic pattern of prostate cancer bone metastases</dc:title>
<dc:description xml:lang="en">The current protocols include the bone scintigraphy and choline PET/CT to localize recurrence in patients having elevated serum PSA after treatment for prostate cancer. Both methods show good agreement in the diagnosis of bone metastases, however conflicting results can be found. We present three cases in which a PET/CT was performed with 18F-Fluoride due to disagreement between the bone scintigraphy and 11C-Choline PET/CT. The 18F-Fluoride PET/CT was capable of confirming the existence of bone metastasis in all of them, so it may be an alternative to the MRI as a tracer of second bone imaging modality, although its use is limited by cost and availability (AU)</dc:description>
<dc:creator>Lomeña, F</dc:creator>
<dc:creator>Moragas, M</dc:creator>
<dc:creator>Soler, M</dc:creator>
<dc:creator>Valls, E</dc:creator>
<dc:creator>García, J. R</dc:creator>
<dc:creator>Riera, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los protocolos actuales incluyen a la gammagrafia ósea y a la PET/TC con colina para localizar la recidiva en pacientes tratados por un cáncer de próstata que presentan elevación de PSA sérico. Existe una buena concordancia entre ambos métodos en el diagnóstico de las metástasis óseas, pero puedan darse resultados discordantes. Presentamos 3 casos en los hemos realizado una PET/TC con 18F-fluoruro, ante una discordancia entre la gammagrafia ósea y la PET/TC con 11C-colina. En ellos, el uso de 18F-fluoruro ha podido corroborado la existencia de metástasis óseas, por lo que puede ser una alternativa como trazador de segunda modalidad de imagen ósea a la RM, si bien su uso esta limitado por su coste y disponibilidad (AU)</dc:description>
<dc:source>Rev. esp. med. nucl. imagen mol. (Ed. impr.);32(1): 33-36, ene.-feb. 2013. ilus</dc:source>
<dc:identifier>ibc-108338</dc:identifier>
<dc:title xml:lang="es">Perfil metabólico y osteogénico de las metástasis óseas por cáncer de próstata</dc:title>
<dc:subject>^d54666^s22074</dc:subject>
<dc:subject>^d24403^s29166</dc:subject>
<dc:subject>^d11914^s29166</dc:subject>
<dc:subject>^d^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8837^s22022</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d54666^s22045</dc:subject>
<dc:subject>^d54666^s22066</dc:subject>
<dc:subject>^d11914^s22044</dc:subject>
<dc:subject>^d9557^s22012</dc:subject>
<dc:subject>^d54666^s22039</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d33478</dc:subject>
<dc:subject>^d9557^s29166</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:subject>^d9555^s29166</dc:subject>
<dc:type>article</dc:type>
<dc:date>201302</dc:date>
</metadata>
</record>
</ibecs-document>
